CalciMedica (NASDAQ:CALC) Announces Earnings Results, Beats Expectations By $0.02 EPS

CalciMedica (NASDAQ:CALC) announced its earnings results on Wednesday. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.02, Zacks reports.

CalciMedica Trading Down 4.5%

CALC stock traded down $0.15 during trading on Thursday, hitting $3.19. 16,666 shares of the company traded hands, compared to its average volume of 48,672. The company has a debt-to-equity ratio of 1.39, a quick ratio of 5.45 and a current ratio of 5.45. The company has a 50-day moving average of $3.14 and a 200-day moving average of $2.56. The firm has a market capitalization of $45.94 million, a PE ratio of -1.99 and a beta of 1.37. CalciMedica has a 1 year low of $1.42 and a 1 year high of $4.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, CalciMedica currently has an average rating of “Hold” and a consensus price target of $16.00.

Insider Activity

In other news, insider Eric W. Roberts bought 9,200 shares of the company’s stock in a transaction on Thursday, August 28th. The shares were acquired at an average cost of $2.86 per share, with a total value of $26,312.00. Following the completion of the transaction, the insider owned 70,107 shares of the company’s stock, valued at approximately $200,506.02. This trade represents a 15.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sudarshan Hebbar bought 9,563 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The stock was bought at an average cost of $2.82 per share, for a total transaction of $26,967.66. Following the completion of the acquisition, the insider owned 61,539 shares in the company, valued at $173,539.98. This trade represents a 18.40% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 48,782 shares of company stock valued at $140,231 over the last 90 days. 41.55% of the stock is currently owned by company insiders.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. Envestnet Asset Management Inc. lifted its holdings in CalciMedica Inc. (NASDAQ:CALC) by 58.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 93,433 shares of the company’s stock after buying an additional 34,386 shares during the period. Envestnet Asset Management Inc. owned about 0.67% of CalciMedica worth $149,000 at the end of the most recent reporting period.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.